May 23, 2020 / 12:10 AM / 7 days ago

BRIEF-Gilead Sciences Issues Statement On NEJM Publication Of Remdesivir Data From NIAID Study

May 22 (Reuters) - Gilead Sciences Inc:

* GILEAD SCIENCES STATEMENT ON NEJM PUBLICATION OF REMDESIVIR DATA FROM NIAID STUDY

* FINDINGS FROM NIAID TRIAL OF REMDESIVIR IN HOSPITALIZED PATIENTS WITH ADVANCED COVID-19 HAVE BEEN PUBLISHED IN PEER-REVIEWED MEDICAL JOURNAL

* FINDINGS SUPPORT USE OF REMDESIVIR IN POPULATION, WITH LARGEST BENEFIT OBSERVED AMONG INDIVIDUALS WHO REQUIRED OXYGEN SUPPLEMENTATION

* ANTICIPATE THAT RESULTS FROM PHASE 3 SIMPLE-SEVERE STUDY WILL BE PUBLISHED IN NEAR FUTURE

* DATA FROM SIMPLE-SEVERE STUDY SUPPORT TREATMENT OF SOME PATIENTS FOR 5 DAYS RATHER THAN 10 DAYS, DEPENDING ON CLINICAL STATUS

* RESULTS FROM PHASE 3 SIMPLE-MODERATE STUDY ARE EXPECTED AT END OF THIS MONTH Source: bit.ly/3d2rxve Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below